ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
Population-Level Frequency of Fluoroquinolone Resistance by Whole-Genome Sequencing Drug Predictions in Mycobacterium tuberculosis Complex Isolates in England From 2017 Through 2023.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Fluoroquinolone resistance and mutation profiles inFrontiers in public health · 2026Article
- Fluoroquinolone and Second-Line Injectable Resistance Among Rifampicin- and Isoniazid-ResistantMicroorganisms · 2025Article
- Diagnostics and new treatment regimens for TB: can the Xpert MTB/XDR assay fill the gap for fluoroquinolone testing?Journal of clinical microbiology · 2025Article
- Genomic epidemiology of Mycobacterium tuberculosis in Wales.Scientific reports · 2025Article
- Operational considerations of select new treatment recommendations for drug-susceptible and drug-resistant tuberculosis.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fluoroquinolones are increasingly important for anti-tuberculosis (TB) treatment. Identifying fluoroquinolone resistance (FR) is essential. Using sequencing data from over 16 000 unselected isolates, this first English survey of FR, found it present in 1.4% overall and 23.9% of multidrug-resistant TB. Routine sequencing allows clinically-relevant resistance surveillance and should be widely adopted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.